Company, co-founded by physician-turned-venturepreneur Dr. Jonathan E. Lim, is targeting undisclosed biological drivers of cancer SAN DIEGO, December 18, 2018-- Erasca, a company dedicated to advancing exceptional scientific approaches to erase cancer, has completed a $42 million Series A financing round co-led by founding investors City Hill Ventures and Cormorant Asset Management, joined by additional institutional and individual investors. Proceeds of the financing will support development of a new generation of oncology drugs intended to not just treat, but actually cure cancer. "Cancer is a pervasive disease that has impacted nearly everyone I know in some way.